About Andrew Crenshaw:
Andrew Crenshaw, M.S. is Vice President of Operations and RTP Site Head at Grail. Prior to joining GRAIL, Andrew worked at Q2 Solutions as their Global CDx Discipline Director. He worked with leading Pharmaceuticals and Technology partners to clinically validate potential Companion Diagnostics in over 150 global clinical trials. Andrew has more than 20 years of experience in the clinical and biomedical research industry and has broad experience in translating strategy into operational activities, performance and relationship management, and continuous improvement. Andrew holds a B.S. in Microbiology from North Carolina State University and a Masters of Science in Biotechnology from University of Maryland University College. Andrew is a native North Carolinian and lives in Wake Forest, NC with his wife and three children.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges with Galleri™, GRAIL’s multi-cancer early detection test. An earlier version of Galleri demonstrated the ability to detect more than 50 types of cancers — over 45 of which lack recommended screening tests today — with a low false-positive rate of less than 1%. When cancer is detected, Galleri localizes the cancer signal with high accuracy, all from a single blood draw. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.
GRAIL recently announced it expects to hire more than 100 employees at its new state-of-the-art laboratory facility located in Research Triangle Park this year.